Receive our newsletter – data, insights and analysis delivered to you
June 15, 2009

Eli Lilly Launches Initiative to Find New Drugs

Eli Lilly has launched a new initiative to discover drugs in new and unmet diseases including Alzheimer's disease, cancer, diabetes and osteoporosis. The company has launched the initiative, known as the Lilly Phenotypic Drug Discovery Initiative or PD2, to foster open collaboration betw

By cms admin

Eli Lilly has launched a new initiative to discover drugs in new and unmet diseases including Alzheimer’s disease, cancer, diabetes and osteoporosis.

The company has launched the initiative, known as the Lilly Phenotypic Drug Discovery Initiative or PD2, to foster open collaboration between the company and global laboratory researchers.

Lilly vice president of discovery chemistry research and technologies Alan Palkowitz said that every year, researchers throughout the world design and synthesise compounds in university and biotechnology laboratories that are never fully evaluated as potential drug candidates.

“There’s an untapped source of ideas and compounds in the greater scientific community that could ultimately impact patients’ lives following further evaluation and development,” Palkowitz said.

The initiative will make use of Lilly-developed disease-state assays and the company’s secure web portal, to evaluate the therapeutic potential of compounds synthesised in university and biotechnology laboratories.

Findings from this initiative could then form the basis for collaboration or licensing agreements between Lilly and external institutions.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU